<DOC>
	<DOCNO>NCT02194179</DOCNO>
	<brief_summary>The objective establish pharmacokinetic ( PK ) profile steady state two different nevirapine ( NVP ) extend release ( XR ) formulations 300 mg 400 mg daily ( QD ) fast fed condition comparison commercially available NVP immediate release ( IR ) tablet 200 mg BID ( 400 mg/day ) .</brief_summary>
	<brief_title>Bioavailability 2 Different Nevirapine Extended Release Formulations Compared Viramune® HIV-1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>HIV1 infect male female ≥ 18 ≤ 60 year age Body mass index 18.5 29.9 kg/m2 , inclusive Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Treated stable Viramune® BID base regimen since least 12 week prior study entry . If however , subject 's current Viramune® treatment consist two 200mg tablet daily ( prescribed label ) , subject allow participate he/she agree switch Viramune® 200mg twice daily , 14 day start Nevirapine Extended Release . An HIV1 viral load ≤ 50 c/mL screen Acceptable screen laboratory value indicate adequate baseline organ function follow exception : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5 time upper limit normal ( ULN ) ( DAIDS Grade 1 ) Gammaglutamyl transferase ( GGT ) &lt; 2.5 time ULN ( DAIDS Grade 1 ) Willingness abstain alcoholic beverage 24 hour prior intensive pharmakokinetic sampling day Willingness abstain ingest substance may alter drug plasma level interaction cytochrome P450 system study Willingness abstain grapefruit grapefruit juice , Seville oranges juice , St John 's wort milk thistle start 14 day prior administration study medication end study , Karnofsky performance score ≥70 Current treatment PI Participation another trial investigational medicine within two month prior Day 1 study Serum creatinine level &gt; 1.5 time ULN screen History acute illness within 60 day prior Day 1 , would make subject , opinion investigator , unsuitable trial History evidence severe illness , malignancy condition would make subject , opinion investigator , unsuitable trial Any evidence clinically relevant concomitant disease , include gastrointestinal , hepatic , renal disorder clinical relevance Surgery gastrointestinal tract ( except appendectomy herniotomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder Chronic relevant acute infection HIV1 ( e.g . hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) co infection : A chronic acute HBV infection define : HBs Ag positive . Chronic acute HCV infection define : HCV Ab positive 1 confirm positive viral load measurement precede study entry ) Alcohol substance abuse within 6 month prior screen study Inability comply protocol requirement Screening laboratory value &lt; DAIDS grade 1 All fertile male female , respective partner ( ) willing use two form effective contraception . A doublebarrier method must use . A doublebarrier method define e.g . : 1 ) condom spermicidal jelly foam suppository ; 2 ) diaphragm spermicide ; 3 ) male condom diaphragm Female childbearing potential : Has positive serum pregnancy test screening , Is breastfeed , Is plan become pregnant , Is willing use barrier method protection require ethinyl estradiol administration Any AIDSdefining illness unresolved , symptomatic , stable treatment least 12 week screen visit HIV2 infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>